Condition
Lung Cancer Squamous Cell
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownTo Evaluate the Efficacy and Safety of Inhaled Corticosteroids Combined With Bronchodilators and Programmed Death-ligand 1 (PD-L1) Inhibitor Plus Platinum-based Chemotherapy in Patients With Advanced Lung Squamous Cell Carcinoma Complicated With Chronic Obstructive Pulmonary Disease (COPD)NCT06772454 · 2023-01-01
RECRUITINGBispecific PSMAxCD3 Antibody CC-1 in Patients With Squamous Cell Carcinoma of the LungNCT04496674 · 2022-02-02
TERMINATEDGlypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the LungNCT05228795 · 2022-02-01
UNKNOWNElectrocautery Ablation for the Prevention of Lung CancerNCT03870152 · 2020-10-29
TERMINATEDStudy of CT and MR in the Lung CancerNCT04034667 · 2019-09-01
UNKNOWNA Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLCNCT03668496 · 2018-11-09
UNKNOWNStudy of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsNCT03065062 · 2017-02-28
SUSPENDEDCommon interventions
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
UNKNOWN3
TERMINATED2
RECRUITING1
SUSPENDED1
Phase mix
PHASE12
PHASE22
PHASE32
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.